登录
 机构网站
  1. 首页
  2. 情报产品
  3. 快讯详情

《CELL，4月29日，Adjunct immunotherapies for the management of severely ill COVID-19 patients》

  • 来源专题：COVID-19科研动态监测
  • 编译者： xuwenwhlib
  • 发布时间：2020-05-03

  • Adjunct immunotherapies for the management of severely ill COVID-19 patients

    Srinivasa Reddy Bonam Srini V. Kaveri Anavaj Sakuntabhai Laurent Gilardin Jagadeesh Bayry

    Open AccessPublished:April 29, 2020DOI:https://doi.org/10.1016/j.xcrm.2020.100016

    Abstract

    Coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). It has infected millions with more than 181,000 fatal cases as of 22nd April 2020. Currently, there are no specific COVID-19 therapies. Most patients depend on mechanical ventilation. Current COVID-19 data clearly highlight that cytokine storm and activated immune cell migration to the lungs characterize the early immune response to COVID-19 that causes severe lung damage and development of acute respiratory distress syndrome. In view of uncertainty associated with immunosuppressive treatments such as corticosteroids and their possible secondary effects, including risks of secondary infections, we suggest immunotherapies as an adjunct therapy in severe COVID-19 cases. Such immunotherapies based on inflammatory cytokine neutralization, immunomodulation and passive viral neutralization, not only reduce inflammation, inflammation-associated lung damage, or viral load, but could also prevent intensive care unit hospitalization and dependency on mechanical ventilation both of which are limited resources.

  • 原文来源：https://www.cell.com/cell-reports-medicine/fulltext/S2666-3791(20)30021-5
17浏览量
原文链接
相关报告

  • 《4月29日_治疗重症COVID-19患者的辅助免疫疗法》
    • 来源专题：COVID-19科研动态监测
    • 编译者：zhangmin
    • 发布时间：2020-05-03
    • 1.时间：2020年4月29日 2.机构或团队：巴黎大学、法国巴斯德研究所、法国贝金医院 3.事件概要： 4月29日，Cell Reports Medicine期刊发表了来自巴黎大学、法国巴斯德研究所、法国贝金医院研究团队的题为“Adjunct immunotherapies for the management of severely ill COVID-19 patients”的文章。 文章指出，目前，尚无特定的COVID-19治疗方法，大多数患者依靠机械通气。当前的COVID-19数据清楚地表明，细胞因子风暴和活化的免疫细胞向肺部迁移是对COVID-19的早期免疫反应的特征，这会导致严重的肺损伤和急性呼吸窘迫综合征的发展。考虑到与免疫抑制疗法（如皮质类固醇）相关的不确定性及其可能的继发作用（包括继发感染的风险），该文章建议在严重的COVID-19病例中将免疫疗法作为辅助疗法。这种基于炎性细胞因子中和，免疫调节和被动病毒中和的免疫疗法，不仅可以减少炎症、炎症相关的肺损伤或病毒载量，而且还可以防止重症监护病房的住院和对机械通气的依赖（这两者都是有限的资源）。 4.附件： 原文链接https://www.cell.com/cell-reports-medicine/fulltext/S2666-3791(20)30021-5
    77浏览量
    原文链接

  • 《PNAS，4月29日，Effective treatment of severe COVID-19 patients with tocilizumab》
    • 来源专题：COVID-19科研动态监测
    • 编译者：xuwenwhlib
    • 发布时间：2020-05-01
    • Effective treatment of severe COVID-19 patients with tocilizumab Xiaoling Xu, View ORCID ProfileMingfeng Han, Tiantian Li, Wei Sun, View ORCID ProfileDongsheng Wang, Binqing Fu, Yonggang Zhou, Xiaohu Zheng, View ORCID ProfileYun Yang, Xiuyong Li, Xiaohua Zhang, Aijun Pan, and Haiming Wei PNAS first published April 29, 2020 https://doi.org/10.1073/pnas.2005615117 Edited by Zhu Chen, Shanghai Jiao Tong University, Shanghai, China, and approved April 14, 2020 (received for review March 25, 2020) Abstract After analyzing the immune characteristics of patients with severe coronavirus disease 2019 (COVID-19), we have identified that pathogenic T cells and inflammatory monocytes with large amount of interleukin 6 secreting may incite the inflammatory storm, which may potentially be curbed through monoclonal antibody that targets the IL-6 pathways. Here, we aimed to assess the efficacy of tocilizumab in severe patients with COVID-19 and seek a therapeutic strategy. The patients diagnosed as severe or critical COVID-19 in The First Affiliated Hospital of University of Science and Technology of China (Anhui Provincial Hospital) and Anhui Fuyang Second People’s Hospital were given tocilizumab in addition to routine therapy between 5 and 14 February 2020. The changes of clinical manifestations, computerized tomography (CT) scan image, and laboratory examinations were retrospectively analyzed. Fever returned to normal on the first day, and other symptoms improved remarkably within a few days. Within 5 d after tocilizumab, 15 of the 20 patients (75.0%) had lowered their oxygen intake, and 1 patient needed no oxygen therapy. CT scans manifested that the lung lesion opacity absorbed in 19 patients (90.5%). The percentage of lymphocytes in peripheral blood, which decreased in 85.0% of patients (17/20) before treatment (mean, 15.52 ± 8.89%), returned to normal in 52.6% of patients (10/19) on the fifth day after treatment. Abnormally elevated C-reactive protein decreased significantly in 84.2% of patients (16/19). No obvious adverse reactions were observed. All patients have been discharged on average 15.1 d after giving tocilizumab. Preliminary data show that tocilizumab, which improved the clinical outcome immediately in severe and critical COVID-19 patients, is an effective treatment to reduce mortality.
    115浏览量
    原文链接